SCHEMBL1895519

SCHEMBL1895519

Cc1c(Cl)c(O)c(C(=O)Nc2nccs2)c(=O)n1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.51
ALDH1A1 P00352 5/20 0.51
MAPT P10636 4/20 0.51
KDM4E B2RXH2 3/20 0.51
HTT P42858 3/20 0.51
USP2 O75604 1/20 0.51
TSHR P16473 2/20 0.48
NPC1 O15118 7/20 0.47
RAB9A P51151 7/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
POLB P06746 2/20 0.47
BLM P54132 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
MAPK1 P28482 1/20 0.47
SMN1; SMN2 Q16637 4/20 0.46
PPARG P37231 1/20 0.46
NCOR2 Q9Y618 1/20 0.46
AHR P35869 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1883150 0.81 ALDH1A1 (0.48) LMNAALDH1A1KDM4ETSHRRAB9A
SCHEMBL1889947 0.78 RAB9A (0.51) LMNAALDH1A1MAPTKDM4EHTT
SCHEMBL10674202 0.77 RAB9A (0.69) LMNAALDH1A1MAPTKDM4EHTT
SCHEMBL1777791 0.77 NPC1 (0.47) LMNAALDH1A1MAPTKDM4EHTT
SCHEMBL1885161 0.74 NPC1 (0.42) LMNAALDH1A1MAPTKDM4EHTT
SCHEMBL10672321 0.73 RAB9A (0.50) LMNAALDH1A1MAPTKDM4EHTT
SCHEMBL12417654 0.73 TSHR (0.39) LMNAALDH1A1MAPTKDM4EUSP2
SCHEMBL1780290 0.72 NPC1 (0.44) LMNAALDH1A1MAPTKDM4EHTT
SCHEMBL9194214 0.72 KDM4E (0.53) LMNAALDH1A1MAPTKDM4EHTT
SCHEMBL16073042 0.71 NPC1 (0.58) LMNAALDH1A1MAPTKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1887002-B1 CARBOXAMIDE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2015-08-26 EP disclosed
US-8304437-B2 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-11-06 US disclosed
US-8304437-B2 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-11-06 US disclosed
US-20110172276-A1 CARBOXAMIDE COMPOUND AND USE OF THE SAME ARIMORI SADAYUKI 2011-07-14 US disclosed
US-20110172276-A1 CARBOXAMIDE COMPOUND AND USE OF THE SAME ARIMORI SADAYUKI 2011-07-14 US disclosed
US-7935716-B2 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-05-03 US disclosed
US-7935716-B2 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-05-03 US disclosed
US-7935716-B2 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-05-03 US disclosed
US-20090076063-A1 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-03-19 US disclosed
US-20090076063-A1 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-03-19 US disclosed
US-20090076063-A1 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-03-19 US disclosed
EP-1887002-A1 CARBOXAMIDE COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2008-02-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076063-A1 Carboxamide compound and use of the same CBR3, SIRT2, SIRT1 LMNA 1426/4885ALDH1A1 3016/4885MAPT 3161/4885
US-20110172276-A1 CARBOXAMIDE COMPOUND AND USE OF THE SAME CBR3, SIRT2, SIRT1 LMNA 1426/4885ALDH1A1 3016/4885MAPT 3161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.